Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 11
2008 4
2009 1
2010 6
2011 3
2012 5
2013 7
2014 9
2015 5
2016 2
2017 4
2018 4
2019 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

58 results
Results by year
Filters applied: . Clear all
Page 1
Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.
Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB. Locatelli F, et al. Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1701-1710. doi: 10.2215/CJN.01380219. Epub 2019 Aug 16. Clin J Am Soc Nephrol. 2019. PMID: 31420350 Free PMC article. Clinical Trial.
We compared cardiovascular outcomes and all-cause mortality associated with monthly methoxy polyethylene glycol-epoetin beta with those of the shorter-acting agents epoetin alfa/beta and darbepoetin alfa in patients with anemia of …
We compared cardiovascular outcomes and all-cause mortality associated with monthly methoxy polyethylene glycol-epoe
Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial.
Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, Canaud B, Kerr PG, Macdougall IC, Besarab A, Villa G, Kazes I, Van Vlem B, Jolly S, Beyer U, Dougherty FC; PATRONUS Investigators. Carrera F, et al. Nephrol Dial Transplant. 2010 Dec;25(12):4009-17. doi: 10.1093/ndt/gfq305. Epub 2010 Jun 3. Nephrol Dial Transplant. 2010. PMID: 20522670 Free PMC article. Clinical Trial.
We report results of a multi-national, randomized, prospective trial comparing haemoglobin maintenance with methoxy polyethylene glycol-epoetin beta and darbepoetin alfa administered once monthly. ...Doses increased by 6.8% with methoxy
We report results of a multi-national, randomized, prospective trial comparing haemoglobin maintenance with methoxy polyethylene
Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).
Levin NW, Fishbane S, Cañedo FV, Zeig S, Nassar GM, Moran JE, Villa G, Beyer U, Oguey D; MAXIMA study investigators. Levin NW, et al. Lancet. 2007 Oct 20;370(9596):1415-21. doi: 10.1016/S0140-6736(07)61599-2. Lancet. 2007. PMID: 17950856 Clinical Trial.
We aimed to compare the effectiveness of methoxy polyethylene glycol-epoetin beta, given intravenously at 2-week or 4-week intervals, with epoetin treatment one to three times per week for haemoglobin control in haemodialysis patients. .. …
We aimed to compare the effectiveness of methoxy polyethylene glycol-epoetin beta, given intravenously at …
Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration.
Fishbane S, Pannier A, Liogier X, Jordan P, Dougherty FC, Reigner B. Fishbane S, et al. J Clin Pharmacol. 2007 Nov;47(11):1390-7. doi: 10.1177/0091270007307570. J Clin Pharmacol. 2007. PMID: 17962427 Clinical Trial.
C.E.R.A. (methoxy polyethylene glycol-epoetin beta), a continuous erythropoietin receptor activator, differs from traditional erythropoiesis-stimulating agents in its pharmacokinetic and receptor binding proper …
C.E.R.A. (methoxy polyethylene glycol-epoetin beta), a continuous erythropoietin recepto
Effect of methoxy polyethylene glycol-epoetin beta on oxidative stress in predialysis patients with chronic kidney disease.
Bartnicki P, Fijałkowski P, Majczyk M, Błaszczyk J, Banach M, Rysz J. Bartnicki P, et al. Med Sci Monit. 2013 Nov 8;19:954-9. doi: 10.12659/MSM.884024. Med Sci Monit. 2013. PMID: 24201565 Free PMC article. Clinical Trial.
The aim of the current study was to investigate the effect of a long half-life ESA, methoxy polyethylene glycol-epoetin beta (Mircera), on some markers of oxidative stress in predialysis patients with CKD. ...CONCLUSIONS: Our results suggest tha …
The aim of the current study was to investigate the effect of a long half-life ESA, methoxy polyethylene glycol-epoe
Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U. Klinger M, et al. Am J Kidney Dis. 2007 Dec;50(6):989-1000. doi: 10.1053/j.ajkd.2007.08.013. Am J Kidney Dis. 2007. PMID: 18037099 Clinical Trial.
BACKGROUND: C.E.R.A. (methoxy polyethylene glycol-epoetin beta), a continuous erythropoietin receptor activator, was developed to provide stable control of hemoglobin (Hb) levels at extended administration intervals i …
BACKGROUND: C.E.R.A. (methoxy polyethylene glycol-epoetin beta), a continuous erythropoietin
Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
Fischbach M, Wühl E, Reigner SCM, Morgan Z, Schaefer F. Fischbach M, et al. Clin J Am Soc Nephrol. 2018 Jan 6;13(1):81-90. doi: 10.2215/CJN.03570417. Epub 2017 Nov 2. Clin J Am Soc Nephrol. 2018. PMID: 29097481 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVES: The study was conducted to identify a conversion factor for switching from previous erythropoiesis-stimulating agents (ESAs) to continuous erythropoietin receptor activator-methoxy polyethylene glycol- …
BACKGROUND AND OBJECTIVES: The study was conducted to identify a conversion factor for switching from previous erythropoiesis-stimulating ag …
Indexes of the erythropoietin level in the blood plasma of chronic heart failure patients with anemia.
Zahidova KK. Zahidova KK. J Basic Clin Physiol Pharmacol. 2018 Jan 26;29(1):11-17. doi: 10.1515/jbcpp-2016-0102. J Basic Clin Physiol Pharmacol. 2018. PMID: 29220885 Clinical Trial.
Before treatment, the patients underwent the following medical therapy: angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, long-acting nitrates, diuretics, digoxin, and beta-blockers at individual doses. ...The EPO level in the blood plasma …
Before treatment, the patients underwent the following medical therapy: angiotensin-converting enzyme inhibitors, angiotensin II receptor
Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
Otsuka T, Sakai Y, Yui S, Sukegawa M, Suzuki A, Mugishima K, Sumi Y, Otsuka Y, Tsuruoka S. Otsuka T, et al. J Nippon Med Sch. 2015;82(1):21-6. doi: 10.1272/jnms.82.21. J Nippon Med Sch. 2015. PMID: 25797871 Free article. Clinical Trial.
Furthermore, the change ratio of the dose of sustained ESAs reportedly ranges from 0.8 to 1.3. In the present study, to compare darbepoetin alfa and epoetin beta pegol (a continuous erythropoietin receptor activator [CERA]), we examined t …
Furthermore, the change ratio of the dose of sustained ESAs reportedly ranges from 0.8 to 1.3. In the present study, to compare darbepoetin …
Treatment of anemia with epoetin in kidney transplant recipients.
Bren A, Arnol M, Kandus A, Varl J, Oblak M, Lindič J, Pajek J, Knap B, Kovač D, Mlinšek G, Buturović-Ponikvar J. Bren A, et al. Ther Apher Dial. 2011 Jun;15(3):257-60. doi: 10.1111/j.1744-9987.2011.00947.x. Ther Apher Dial. 2011. PMID: 21624072 Clinical Trial.
The aim of this study was to analyze the prevalence and efficacy of renal anemia treated with epoetin in maintenance kidney transplant recipients in Slovenia. By the end of 2009, 107 out of 537 patients (19.9%) had been treated with epoetin. A cohort of 49 patients …
The aim of this study was to analyze the prevalence and efficacy of renal anemia treated with epoetin in maintenance kidney transplan …
58 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page